The Global Resource For Connecting Buyers and Sellers

BerGenBio: Encouraging I-O Clinical Data With Selective AXL Inhibitor Bemcentinib (BGB324) Supports its Potential as Cornerstone of Cancer Therapy

Favourable interim safety data reported across three phase II clinical trials with bemcentinib in combination with KEYTRUDA® (pembrolizumab)
Immune response demonstrated in AML patients treated with bemcentinib monotherapy in phase II clinical trial
Two posters featuring…